Epstein-Barr virus (EBV) is a highly prevalent virus among adults worldwide. In an immunocompetent individual, EBV infection generally results in lifelong latency of the virus and no sequelae. However, in the setting of immune dysfunction, EBV can induce the development of autoimmune disorders, hyperplastic proliferations, and cancers, including lymphoma. Here, we explore the pathogenic and oncogenic role of EBV in Burkitt lymphoma, diffuse large B-cell lymphoma, Hodgkin lymphoma, plasmablastic lymphoma, lymphomatoid granulomatosis, and post-transplant lymphoproliferative disorders and lymphoproliferative disorders associated with immune deficiency and dysregulation. In addition to describing general mechanisms of EBV-associated oncogenesis, we also discuss EBV-associated oncogenesis in the context of each disorder, as well as their microscopic, phenotypic, and clinical presentations.
HadinotoVShapiroMSunCCThorley-LawsonDA. The dynamics of EBV shedding implicate a central role for epithelial cells in amplifying viral output. PLoS Pathog. 2009;5(7):e1000496. doi:https://doi.org/10.1371/journal.ppat.1000496.
SylvesterJEBuchananBKSilvaTW. Infectious mononucleosis: rapid evidence review. Am Fam Physician. 2023;107(1):71–78.
4.
ZhangL. A common mechanism links Epstein-Barr virus infections and autoimmune diseases. J Med Virol. 2023;95(1):e28363. doi:https://doi.org/10.1002/jmv.28363.
5.
AllenUDPreiksaitisJK, AST Infectious Diseases Community of Practice. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33(9):e13652. doi:https://doi.org/10.1111/ctr.13652
6.
AlaggioRAmadorCAnagnostopoulosI, et al.The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms [published correction appears in Leukemia. 2023 Sep;37(9):1944-1951]. Leukemia. 2022;36(7):1720–1748. doi:https://doi.org/10.1038/s41375-022-01620-2.
7.
CampoEJaffeESCookJR, et al.The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee [published correction appears in Blood. 2023 Jan 26;141(4):437]. Blood. 2022;140(11):1229–1253. doi:https://doi.org/10.1182/blood.2022015851.
8.
DowdJBPalermoTBriteJMcDadeTWAielloA. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010. PLoS One. 2013;8(5):e64921. Published 2013 May 22. doi:https://doi.org/10.1371/journal.pone.0064921
SolomayTVSemenenkoTAKarazhasNV, et al.Assessing risks of infection with herpes viruses during transfusion of donor blood and its components. Health Risk Analysis. 2020;(2):135–142. doi:https://doi.org/10.21668/health.risk/2020.2.15.eng.
11.
GongSCraneGMMcCallCM, et al.Expanding the Spectrum of EBV-positive marginal zone lymphomas: a lesion associated with diverse immunodeficiency settings. Am J Surg Pathol. 2018;42(10):1306–1316. doi:https://doi.org/10.1097/PAS.0000000000001113.
12.
MackridesNCampuzano-ZuluagaGMaque-AcostaY, et al.Epstein-Barr virus- positive follicular lymphoma. Mod Pathol. 2017;30(4):519–529. doi:https://doi.org/10.1038/modpathol.2016.214.
13.
LoghaviSKhouryJDMedeirosLJ. Epstein-Barr virus-positive plasmacytoma in immunocompetent patients. Histopathology. 2015;67(2):225–234. doi:https://doi.org/10.1111/his.12640.
14.
BalfourHHJrDunmireSKHogquistKA. Infectious mononucleosis. Clin Transl Immunology. 2015;4(2):e33. Published 2015 Feb 27. doi:https://doi.org/10.1038/cti.2015.1
15.
De WaeleMThielemansCVan CampBK. Characterization of immunoregulatory T cells in EBV-induced infectious mononucleosis by monoclonal antibodies. N Engl J Med. 1981;304(8):460–462. doi:https://doi.org/10.1056/NEJM198102193040804.
16.
TanJWHuJR. Fever with atypical lymphocytosis: pearls and pitfalls in Epstein-Barr virus serology. BMJ Case Rep. 2023;16(5):e250081. Published 2023 May 3. doi:https://doi.org/10.1136/bcr-2022-250081
17.
FanelliIRoveroPHansenPRFrederiksenJLHouenGTrierNH. Reactivity of rheumatoid arthritis-associated citrulline-dependent antibodies to Epstein-Barr virus nuclear Antigen1-3. Antibodies (Basel). 2022;11(1):20. Published 2022 Mar 11. doi:https://doi.org/10.3390/antib11010020
18.
HouenGTrierNH. Epstein-Barr virus and systemic autoimmune diseases. Front Immunol. 2021;11:587380. Published 2021 Jan 7. doi:https://doi.org/10.3389/fimmu.2020.587380
BjornevikKCorteseMHealyBC, et al.Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296–301. doi:https://doi.org/10.1126/science.abj8222.
21.
LevinLIMungerKLO’ReillyEJFalkKIAscherioA. Primary infection with the Epstein-Barr virus and risk of multiple sclerosis. Ann Neurol. 2010;67(6):824–830. doi:https://doi.org/10.1002/ana.21978.
LanzTVBrewerRCHoPP, et al.Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature. 2022;603(7900):321–327. doi:https://doi.org/10.1038/s41586-022-04432-7.
24.
PooleBDScofieldRHHarleyJBJamesJA. Epstein-Barr virus and molecular mimicry in systemic lupus erythematosus. Autoimmunity. 2006;39(1):63–70. doi:https://doi.org/10.1080/08916930500484849.
25.
JogNRJamesJA. Epstein Barr virus and autoimmune responses in systemic lupus erythematosus. Front Immunol. 2021;11:623944. Published 2021 Feb 3. doi:https://doi.org/10.3389/fimmu.2020.623944
26.
HuLTuJGuiJFangMSunL. Landscape of immune cells in systematic lupus erythematosus patients with Epstein-Barr virus infection: assessed by single-cell sequencing. Rheumatology (Oxford). Published online December 11, 2023. doi:https://doi.org/10.1093/rheumatology/kead673
27.
FechtnerSBerensHBemisE, et al.Antibody responses to Epstein-Barr virus in the preclinical period of rheumatoid arthritis suggest the presence of increased viral reactivation cycles. Arthritis Rheumatol. 2022;74(4):597–603. doi:https://doi.org/10.1002/art.41994.
28.
YangLPuJCaiF, et al.Chronic Epstein-Barr virus infection: a potential junction between primary Sjögren’s syndrome and lymphoma. Cytokine. 2023;168:156227. doi:https://doi.org/10.1016/j.cyto.2023.156227.
29.
BarcelosFMartinsCMonteiroR, et al.Association between EBV serological patterns and lymphocytic profile of SjS patients support a virally triggered autoimmune epithelitis. Sci Rep. 2021;11(1):4082. Published 2021 Feb 18. doi:https://doi.org/10.1038/s41598-021-83550-0
IgnatovaESeriakDFedyaninM, et al.Epstein-Barr virus-associated gastric cancer: disease that requires special approach. Gastric Cancer. 2020;23(6):951–960. doi:https://doi.org/10.1007/s10120-020-01095-z.
32.
Montes-MojarroIAFendFQuintanilla-MartinezL. EBV and the pathogenesis of NK/T cell lymphoma. Cancers (Basel). 2021;13(6):1414. Published 2021 Mar 19. doi:https://doi.org/10.3390/cancers13061414
PegoraroFFavreC. Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation. Ann Hematol. 2021;100(4):865–878. doi:https://doi.org/10.1007/s00277-021-04433-y.
35.
YoungLAlfieriCHennessyK, et al.Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989;321(16):1080–1085. doi:https://doi.org/10.1056/NEJM198910193211604.
AbabnehESaadAMCraneGM. The role of EBV in haematolymphoid proliferations: emerging concepts relevant to diagnosis and treatment. Histopathology. 2021;79(4):451–464. doi:https://doi.org/10.1111/his.14379.
38.
KnechtHMcQuainCMartinJ, et al.Expression of the LMP1 oncoprotein in the EBV negative Hodgkin’s disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene. 1996;13(5):947–953.
39.
ZhangJSommermannTLiX, et al.LMP1 And EBNA2 constitute a minimal set of EBV genes for transformation of human B cells. Front Immunol. 2023;14:1331730. Published 2023 Dec 19. doi:https://doi.org/10.3389/fimmu.2023.1331730
40.
MinamitaniTMaYZhouH, et al.Mouse model of Epstein-Barr virus LMP1- and LMP2A-driven germinal center B-cell lymphoproliferative disease. Proc Natl Acad Sci U S A. 2017;114(18):4751–4756. doi:https://doi.org/10.1073/pnas.1701836114.
41.
FishKChenJLongneckerR. Epstein-Barr virus latent membrane protein 2A enhances MYC-driven cell cycle progression in a mouse model of B lymphoma. Blood. 2014;123(4):530–540. doi:https://doi.org/10.1182/blood-2013-07-517649.
42.
HerreroJAMathewPPayaCV. LMP-1 activates NF-kappa B by targeting the inhibitory molecule I kappa B alpha. J Virol. 1995;69(4):2168–2174. doi:https://doi.org/10.1128/JVI.69.4.2168-2174.1995.
43.
UchidaJYasuiTTakaoka-ShichijoY, et al.Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science. 1999;286(5438):300–303. doi:https://doi.org/10.1126/science.286.5438.300.
44.
SunLZhaoYShiHMaCWeiL. LMP-1 induces survivin expression to inhibit cell apoptosis through the NF-κB and PI3K/Akt signaling pathways in nasal NK/T-cell lymphoma. Oncol Rep. 2015;33(5):2253–2260. doi:https://doi.org/10.3892/or.2015.3847.
45.
HendersonSRoweMGregoryC, et al.Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65(7):1107–1115. doi:https://doi.org/10.1016/0092-8674(91)90007-l.
46.
Vento-TormoRRodríguez-UbrevaJLisioLD, et al.NF-κB directly mediates epigenetic deregulation of common microRNAs in Epstein-Barr virus-mediated transformation of B-cells and in lymphomas. Nucleic Acids Res. 2014;42(17):11025–11039. doi:https://doi.org/10.1093/nar/gku826.
47.
MurataTSatoYKimuraH. Modes of infection and oncogenesis by the Epstein-Barr virus. Rev Med Virol. 2014;24(4):242–253. doi:https://doi.org/10.1002/rmv.1786.
48.
CaldwellRGWilsonJBAndersonSJLongneckerR. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity. 1998;9(3):405–411. doi:https://doi.org/10.1016/s1074-7613(00)80623-8.
49.
MillerCLLeeJHKieffELongneckerR. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci U S A. 1994;91(2):772–776. doi:https://doi.org/10.1073/pnas.91.2.772.
50.
YinHQuJPengQGanR. Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis. Med Microbiol Immunol. 2019;208(5):573–583. doi:https://doi.org/10.1007/s00430-018-0570-1.
51.
BochkarevABarwellJAPfuetznerRABochkarevaEFrappierLEdwardsAM. Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. Cell. 1996;84(5):791–800. doi:https://doi.org/10.1016/s0092-8674(00)81056-9.
52.
De LeoACalderonALiebermanPM. Control of viral latency by episome maintenance proteins. Trends Microbiol. 2020;28(2):150–162. doi:https://doi.org/10.1016/j.tim.2019.09.002.
53.
DheekolluJWiedmerAAyyanathanKDeakyneJSMessickTELiebermanPM. Cell-cycle-dependent EBNA1-DNA crosslinking promotes replication termination at oriP and viral episome maintenance. Cell. 2021;184(3):643–654.e13. doi:https://doi.org/10.1016/j.cell.2020.12.022
54.
YinYManouryBFåhraeusR. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science. 2003;301(5638):1371–1374. doi:https://doi.org/10.1126/science.1088902.
55.
DaskalogianniCPyndiahSApcherS, et al.Epstein-Barr virus-encoded EBNA1 and ZEBRA: targets for therapeutic strategies against EBV-carrying cancers. J Pathol. 2015;235(2):334–341. doi:https://doi.org/10.1002/path.4431.
56.
WilsonJBManetEGruffatHBussonPBlondelMFahraeusR. EBNA1: oncogenic activity, immune evasion and biochemical functions provide targets for novel therapeutic strategies against Epstein-Barr virus- associated cancers. Cancers (Basel). 2018;10(4):109. Published 2018 Apr 6. doi:https://doi.org/10.3390/cancers10040109
57.
GruhneBSompallaeRMarescottiDKamranvarSAGastaldelloSMasucciMG. The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species. Proc Natl Acad Sci U S A. 2009;106(7):2313–2318. doi:https://doi.org/10.1073/pnas.0810619106.
58.
GadHKoolmeisterTJemthAS, et al.MTH1 Inhibition eradicates cancer by preventing sanitation of the dNTP pool [published correction appears in Nature. 2017 Apr 26;544(7651):508]. Nature. 2014;508(7495):215–221. doi:https://doi.org/10.1038/nature13181.
59.
WangJNagyNMasucciMG. The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization [published correction appears in Oncogene. 2019 Oct 24]. Oncogene. 2020;39(3):603–616. doi:https://doi.org/10.1038/s41388-019-1003-3.
60.
SahaARobertsonES. Mechanisms of B-cell oncogenesis induced by epstein-barr virus. J Virol. 2019;93(13):e00238–19. Published 2019 Jun 14. doi:https://doi.org/10.1128/JVI.00238-19
61.
KaiserCLauxGEickDJochnerNBornkammGWKempkesB. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol. 1999;73(5):4481–4484. doi:https://doi.org/10.1128/JVI.73.5.4481-4484.1999.
62.
BeerSWangeLEZhangX, et al.EBNA2-EBF1 Complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells. Proc Natl Acad Sci U S A. 2022;119(30):e2200512119. doi:https://doi.org/10.1073/pnas.2200512119.
YanagiYOkunoYNaritaY, et al.RNAseq analysis identifies involvement of EBNA2 in PD-L1 induction during Epstein-Barr virus infection of primary B cells. Virology. 2021;557:44–54. doi:https://doi.org/10.1016/j.virol.2021.02.004.
65.
SampleCParkerB. Biochemical characterization of Epstein-Barr virus nuclear antigen 3A and 3C proteins. Virology. 1994;205(2):534–539. doi:https://doi.org/10.1006/viro.1994.1675.
66.
AlldayMJBazotQWhiteRE. The EBNA3 family: two oncoproteins and a tumour suppressor that are central to the biology of EBV in B cells. Curr Top Microbiol Immunol. 2015;391:61–117. doi:https://doi.org/10.1007/978-3-319-22834-1_3.
67.
PeiYSinghRKShuklaSKLangFZhangSRobertsonES. Epstein-Barr virus nuclear antigen 3C facilitates cell proliferation by regulating cyclin D2. J Virol. 2018;92(18):e00663–18. Published 2018 Aug 29. doi:https://doi.org/10.1128/JVI.00663-18
68.
IwakiriD. Epstein-Barr virus-encoded RNAs: key molecules in viral pathogenesis. Cancers (Basel). 2014;6(3):1615–1630. Published 2014 Aug 6. doi:https://doi.org/10.3390/cancers6031615
69.
YajimaMKandaTTakadaK. Critical role of Epstein-Barr Virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation. J Virol. 2005;79(7):4298–4307. doi:https://doi.org/10.1128/JVI.79.7.4298-4307.2005.
70.
ToczyskiDPMateraAGWardDCSteitzJA. The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes. Proc Natl Acad Sci U S A. 1994;91(8):3463–3467. doi:https://doi.org/10.1073/pnas.91.8.3463.
71.
SharpTVSchwemmleMJeffreyI, et al.Comparative analysis of the regulation of the interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-1 and EBER-2 and adenovirus VAI RNA. Nucleic Acids Res. 1993;21(19):4483–4490. doi:https://doi.org/10.1093/nar/21.19.4483.
72.
SamantaMIwakiriDTakadaK. Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling. Oncogene. 2008;27(30):4150–4160. doi:https://doi.org/10.1038/onc.2008.75.
AhsanuddinSCadwellJBSangalNR, et al.Survival predictors of head and neck Burkitt’s lymphoma: an analysis of the SEER database. Otolaryngol Head Neck Surg. 2022;167(1):79–88. doi:https://doi.org/10.1177/01945998211041533.
75.
MedeirosLJMirandaRNVegaFYinCCLinP. Diagnostic Pathology: Lymph Nodes and Spleen with Extranodal Lymphomas. Elsevier; 2011.
76.
SwerdlowSHCampoEHarrisNL, et al. (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed., Vol. 2. International Agency for Research on Cancer; 2017.
77.
PelicciPGKnowlesDMIIMagrathIDalla-FaveraR. Chromosomal breakpoints and structural alterations of the c-myc locus differ in endemic and sporadic forms of Burkitt lymphoma. Proc Natl Acad Sci U S A. 1986;83(9):2984–2988. doi:https://doi.org/10.1073/pnas.83.9.2984
78.
WoronieckaRRymkiewiczGSzafronLM, et al.Cryptic MYC insertions in Burkitt lymphoma: new data and a review of the literature. PLoS One. 2022;17(2):e0263980. Published 2022 Feb 15. doi:https://doi.org/10.1371/journal.pone.0263980
79.
LópezCKleinheinzKAukemaSM, et al.Genomic and transcriptomic changes complement each other in the pathogenesis of sporadic Burkitt lymphoma. Nat Commun. 2019;10(1):1459. Published 2019 Mar 29. doi:https://doi.org/10.1038/s41467-019-08578-3
80.
GruhneBSompallaeRMasucciMG. Three Epstein-Barr virus latency proteins independently promote genomic instability by inducing DNA damage, inhibiting DNA repair and inactivating cell cycle checkpoints. Oncogene. 2009;28(45):3997–4008. doi:https://doi.org/10.1038/onc.2009.258.
81.
GruhneBKamranvarSAMasucciMGSompallaeR. EBV And genomic instability–a new look at the role of the virus in the pathogenesis of Burkitt’s lymphoma. Semin Cancer Biol. 2009;19(6):394–400. doi:https://doi.org/10.1016/j.semcancer.2009.07.005.
82.
KalchschmidtJSBashford-RogersRPaschosK, et al.Epstein-Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J Exp Med. 2016;213(6):921–928. doi:https://doi.org/10.1084/jem.20160120.
83.
EpeldeguiMHungYPMcQuayAAmbinderRFMartínez-MazaO. Infection of human B cells with Epstein-Barr virus results in the expression of somatic hypermutation- inducing molecules and in the accrual of oncogene mutations. Mol Immunol. 2007;44(5):934–942. doi:https://doi.org/10.1016/j.molimm.2006.03.018.
84.
GrandeBMGerhardDSJiangA, et al.Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. Blood. 2019;133(12):1313–1324. doi:https://doi.org/10.1182/blood-2018-09-871418.
85.
RobbianiDFDeroubaixSFeldhahnN, et al.Plasmodium infection promotes genomic instability and AID-dependent B cell lymphoma. Cell. 2015;162(4):727–737. doi:https://doi.org/10.1016/j.cell.2015.07.019.
86.
BroenKDickensJTrangucciR, et al.Burkitt lymphoma risk shows geographic and temporal associations with Plasmodium falciparum infections in Uganda, Tanzania, and Kenya. Proc Natl Acad Sci U S A. 2023;120(2):e2211055120. doi:https://doi.org/10.1073/pnas.2211055120.
87.
MoormannAMChelimoKSumbaOP, et al.Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis. 2005;191(8):1233–1238. doi:https://doi.org/10.1086/428910.
88.
MünzC. Modulation of Epstein-Barr-Virus (EBV)-associated cancers by co-infections. Cancers (Basel). 2023;15(24):5739. Published 2023 Dec 7. doi:https://doi.org/10.3390/cancers15245739
DojcinovSDFendFQuintanilla-MartinezL. EBV-positive lymphoproliferations of B- T- and NK-cell derivation in non-immunocompromised hosts. Pathogens. 2018;7(1):28. Published 2018 Mar 7. doi:https://doi.org/10.3390/pathogens7010028
91.
TracySIHabermannTMFeldmanAL, et al.Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. Haematologica. 2018;103(2):297–303. doi:https://doi.org/10.3324/haematol.2017.176511.
92.
BourbonEMaucort-BoulchDFontaineJ, et al.Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 2021;5(16):3227–3239. doi:https://doi.org/10.1182/bloodadvances.2021004515.
93.
NanFFZhangLLiL, et al.Clinical features and survival impact of EBV-positive diffuse large B-cell lymphoma with different age cutoffs. Eur Rev Med Pharmacol Sci. 2020;24(17):8947–8956. doi:https://doi.org/10.26355/eurrev_202001_22836.
94.
CastilloJJBeltranBEMirandaRNYoungKHChavezJCSotomayorEM. EBV- positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk- stratification, and management. Am J Hematol. 2016;91(5):529–537. doi:https://doi.org/10.1002/ajh.24370.
95.
SatouANakamuraS. EBV-positive B-cell lymphomas and lymphoproliferative disorders: review from the perspective of immune escape and immunodeficiency. Cancer Med. 2021;10(19):6777–6785. doi:https://doi.org/10.1002/cam4.4198.
96.
OuyangQWagnerWMWalterS, et al.An age-related increase in the number of CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev. 2003;124(4):477–485. doi:https://doi.org/10.1016/s0047-6374(03)00026-5.
97.
Montes-MorenoSOdqvistLDiaz-PerezJA, et al.EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation. Mod Pathol. 2012;25(7):968–982. doi:https://doi.org/10.1038/modpathol.2012.52.
98.
GrewalRKChettyMAbayomiEATomuleasaCFrommJR. Use of flow cytometry in the phenotypic diagnosis of hodgkin’s lymphoma. Cytometry B Clin Cytom. 2019;96(2):116–127. doi:https://doi.org/10.1002/cyto.b.21724.
99.
AnsellSM. Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(11):1478–1488. doi:https://doi.org/10.1002/ajh.26717.
100.
MauraFZicchedduBXiangJZ, et al.Molecular evolution of classic Hodgkin lymphoma revealed through whole-genome sequencing of Hodgkin and Reed Sternberg cells. Blood Cancer Discov. 2023;4(3):208–227. doi:https://doi.org/10.1158/2643-3230.BCD-22-0128.
LouissaintAJrFerryJASoupirCPHasserjianRPHarrisNLZukerbergLR. Infectious mononucleosis mimicking lymphoma: distinguishing morphological and immunophenotypic features. Mod Pathol. 2012;25(8):1149–1159. doi:https://doi.org/10.1038/modpathol.2012.70
104.
IsaacsonPGSchmidCPanLWotherspoonACWrightDH. Epstein-Barr virus latent membrane protein expression by Hodgkin and Reed-Sternberg-like cells in acute infectious mononucleosis. J Pathol. 1992;167(3):267–271. doi:https://doi.org/10.1002/path.1711670302.
105.
MurrayPGYoungLS. An etiological role for the Epstein-Barr virus in the pathogenesis of classical Hodgkin lymphoma. Blood. 2019;134(7):591–596. doi:https://doi.org/10.1182/blood.2019000568.
106.
BechtelDKurthJUnkelCKüppersR. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood. 2005;106(13):4345–4350. doi:https://doi.org/10.1182/blood-2005-06-2342.
107.
LiuLLiuQFengS. Management of Epstein-Barr virus-related post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation. Ther Adv Hematol. 2020;11:2040620720910964. Published 2020 Apr 28. doi:https://doi.org/10.1177/2040620720910964
108.
MeerbachAWutzlerPHäferRZintlFGruhnB. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease. J Med Virol. 2008;80(3):441–454. doi:https://doi.org/10.1002/jmv.21096.
109.
HolmanCJKargerABMullanBDBrundageRCBalfourHHJr. Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant. 2012;26(5):741–747. doi:https://doi.org/10.1111/j.1399-0012.2012.01608.x
110.
Sebelin-WulfKNguyenTDOertelS, et al.Quantitative analysis of EBV-specific CD4/CD8T cell numbers, absolute CD4/CD8T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol. 2007;17(3):203–210. doi:https://doi.org/10.1016/j.trim.2006.10.006.
111.
LeeMAbousaudAHarkinsRA, et al.Important considerations in the diagnosis and management of post-transplant lymphoproliferative disorder. Curr Oncol Rep. 2023;25(8):883–895. doi:https://doi.org/10.1007/s11912-023-01418-0.
112.
Al HamedRBazarbachiAHMohtyM. Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities. Bone Marrow Transplant. 2020;55(1):25–39. doi:https://doi.org/10.1038/s41409-019-0548-7.
113.
OudejansJJJiwaMvan den BruleAJ, et al.Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol. 1995;147(4):923–933.
114.
OuyangPRakusKvan BeurdenSJ, et al.IL-10 encoded by viruses: a remarkable example of independent acquisition of a cellular gene by viruses and its subsequent evolution in the viral genome. J Gen Virol. 2014;95(Pt 2):245–262. doi:https://doi.org/10.1099/vir.0.058966-0
115.
de Waal MalefytRHaanenJSpitsH, et al.Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression. J Exp Med. 1991;174(4):915–924. doi:https://doi.org/10.1084/jem.174.4.915.
116.
MelaniCJaffeESWilsonWH. Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood. 2020;135(16):1344–1352. doi:https://doi.org/10.1182/blood.2019000933.
117.
GuineeDJrJaffeEKingmaD, et al.Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol. 1994;18(8):753–764. doi:https://doi.org/10.1097/00000478-199408000-00001
118.
Teruya-FeldsteinJJaffeESBurdPR, et al.The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. Blood. 1997;90(10):4099–4105.
119.
SongJYPittalugaSDunleavyK, et al.Lymphomatoid granulomatosis–a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol. 2015;39(2):141–156. doi:https://doi.org/10.1097/PAS.0000000000000328.
120.
TanièrePThivolet-BéjuiFVitreyD, et al.Lymphomatoid granulomatosis–a report on four cases: evidence for B phenotype of the tumoral cells. Eur Respir J. 1998;12(1):102–106. doi:https://doi.org/10.1183/09031936.98.12010102.
121.
MatosCGonçalvesAPereiraSGCarolaSBrancoT. Lymphomatoid granulomatosis in HIV-2: a rare entity. Cureus. 2021;13(11):e19992. Published 2021 Nov 29. doi:https://doi.org/10.7759/cureus.19992
122.
SebireNJHaseldenSMaloneMDaviesEGRamsayAD. Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol. 2003;56(7):555–557. doi:https://doi.org/10.1136/jcp.56.7.555.
123.
KobayashiSKikuchiYSatoK, et al.Reversible iatrogenic, MTX-associated EBV-driven lymphoproliferation with histopathological features of a lymphomatoid granulomatosis in a patient with rheumatoid arthritis. Ann Hematol. 2013;92(11):1561–1564. doi:https://doi.org/10.1007/s00277-013-1741-1.
DelecluseHJAnagnostopoulosIDallenbachF, et al.Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89(4):1413–1420.
126.
GuanBZhangXMaHZhouHZhouX. A meta-analysis of highly active anti-retroviral therapy for treatment of plasmablastic lymphoma. Hematol Oncol Stem Cell Ther. 2010;3(1):7–12. doi:https://doi.org/10.1016/s1658-3876(10)50050-5.
127.
ValeraABalaguéOColomoL, et al.IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34(11):1686–1694. doi:https://doi.org/10.1097/PAS.0b013e3181f3e29f.
128.
LaurentCFabianiBDoC, et al.Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. Haematologica. 2016;101(8):976–984. doi:https://doi.org/10.3324/haematol.2016.141978.
129.
GreenMRRodigSJuszczynskiP, et al.Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy [published correction appears in Clin Cancer Res. 2012 Apr 1;18(7):2117]. Clin Cancer Res. 2012;18(6):1611–1618. doi:https://doi.org/10.1158/1078-0432.CCR-11-1942.
130.
ChenBJChapuyBOuyangJ, et al.PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res. 2013;19(13):3462–3473. doi:https://doi.org/10.1158/1078-0432.CCR-13-0855.
